Curcumin triggers p16-dependent senescence in active breast cancer-associated fibroblasts and suppresses their paracrine procarcinogenic effects

Neoplasia (United States)

Volumn 15, Issue 6, 2013, Pages 631-640

  Hendrayani, Siti Fauziah ^a   Al Khalaf, Huda H ^a,b   Aboussekhra, Abdelilah ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA GALACTOSIDASE; BROXURIDINE; CURCUMIN; GELATINASE A; GELATINASE B; HISTONE H2AX; INTERLEUKIN 6; JANUS KINASE 2; KI 67 ANTIGEN; LAMIN A; LAMIN B; PROTEIN P16; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENETIC TRANSFECTION; HISTOGRAM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; UPREGULATION; VIRUS INFECTION;

EID: 84878644283     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13478     Document Type: Article

References (39)

1. Siegel R, Naishadham D, and Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29.
2. Aboussekhra A (2011). Role of cancer-associated fibroblasts in breast cancer development and prognosis. Int J Dev Biol 55, 841-849.
3. Franco OE, Shaw AK, Strand DW, and Hayward SW (2009). Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21, 33-39.
4. Shimoda M, Mellody KT, and Orimo A (2009). Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol 21, 19-25.
5. Kalluri R and Zeisberg M (2006). Fibroblasts in cancer. Nat Rev Cancer 6, 392-401.
6. Albini A and Sporn MB (2007). The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7, 139-147.
7. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, and Aggarwal BB (2008). Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 267, 133-164.
8. Gescher AJ, Sharma RA, and Steward WP (2001). Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol 2, 371-379.
9. Strimpakos AS and Sharma RA (2008). Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10, 511-545.
10. Goel A, Kunnumakkara AB, and Aggarwal BB (2007). Curcumin as "curecumin": from kitchen to clinic. Biochem Pharmacol 19, 19.
11. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C, and Chollet P (2010). Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9, 8-14.
12. Collado M and Serrano M (2010). Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10, 51-57.
13. Hayflick L and Moorhead PS (1961). The serial cultivation of human diploid cell strains. Exp Cell Res 25, 585-621.
14. Campisi J (1996). Replicative senescence: an old lives' tale? Cell 84, 497-500.
15. Campisi J and d'Adda di Fagagna F (2007). Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8, 729-740.
16. Campisi J (2012). Aging, cellular senescence, and cancer. Annu Rev Physiol 75, 685-705.
17. Collado M, Blasco MA, and Serrano M (2007). Cellular senescence in cancer and aging. Cell 130, 223-233.
18. Rodier F and Campisi J (2011). Four faces of cellular senescence. J Cell Biol 192, 547-556.
19. Coppe JP, Desprez PY, Krtolica A, and Campisi J (2010). The senescenceassociated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5, 99-118.
20. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, and Campisi J (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 2853-2868.
21. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, and Campisi J (2009). Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11, 973-979.
22. Al-Mohanna MA, Al-Khalaf HH, Al-Yousef N, and Aboussekhra A (2007). The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light. Nucleic Acids Res 35, 223-233. Epub 2006 Dec 2007.
23. Bond JA, Haughton MF, Rowson JM, Smith PJ, Gire V, Wynford-Thomas D, and Wyllie FS (1999). Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol 19, 3103-3114.
24. Al-Ansari MM, Hendrayani SF, Shehata AI, and Aboussekhra A (2012). p16INK4A represses the paracrine tumor-promoting effects of breast stromal fibroblasts. Oncogene. DOI: 10.1038/onc.2012.270, E-pub ahead of print.
25. Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Tweigeri T, Ajarim D, Alaiya A, Dermime S, and Aboussekhra A (2008). Breast carcinoma- associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 68, 2717-2725.
26. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, et al. (2005). Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25, 7432-7440.
27. Alvarez JV and Frank DA (2004). Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther 3, 1045-1050.
28. Freund A, Laberge RM, Demaria M, and Campisi J (2012). Lamin B1 loss is a senescence-associated biomarker. Mol Biol Cell 23, 2066-2075.
29. Plesca D, Mazumder S, and Almasan A (2008). DNA damage response and apoptosis. Methods Enzymol 446, 107-122.
30. Yegorov YE, Chernov DN, Akimov SS, Akhmalisheva AK, Smirnova YB, Shinkarev DB, Semenova IV, Yegorova IN, and Zelenin AV (1997). Blockade of telomerase function by nucleoside analogs. Biochemistry (Mosc) 62, 1296-1305.
31. Severino J, Allen RG, Balin S, Balin A, and Cristofalo VJ (2000). Is β-galactosidase staining a marker of senescence in vitro and in vivo? Exp Cell Res 257, 162-171.
32. Cho S and Hwang ES (2012). Status of mTOR activity may phenotypically differentiate senescence and quiescence. Mol Cells 33, 597-604.
33. Loeffler M, Kruger JA, Niethammer AG, and Reisfeld RA (2006). Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116, 1955-1962.
34. Parrinello S, Coppe JP, Krtolica A, and Campisi J (2005). Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci 118, 485-496.
35. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, and Roninson IB (1999). A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59, 3761-3767.
36. Roninson IB (2003). Tumor cell senescence in cancer treatment. Cancer Res 63, 2705-2715.
37. Coppe JP, Rodier F, Patil CK, Freund A, Desprez PY, and Campisi J (2011). Tumor suppressor and aging biomarker p16INK4a induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem 286, 36396-36403.
38. Freund A, Orjalo AV, Desprez PY, and Campisi J (2010). Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 16, 238-246.
39. Leontieva OV and Blagosklonny MV (2010). DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging 2, 924-935.